WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma

Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach

(2018) Mathilde R. W. de Jong et al.   PLoS One

Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition

(2017) Xiaoguang Wang et al.   HAEMATOLOGICA

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma

(2017) John P. Leonard et al.   JOURNAL OF CLINICAL ONCOLOGY

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

(2017) Umberto Vitolo et al.   JOURNAL OF CLINICAL ONCOLOGY

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

(2017) Gustaaf W. van Imhoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

(2017) Annalisa Chiappella et al.   LANCET ONCOLOGY

A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia

(2017) Tamara B. Garcia et al.   MOLECULAR CANCER THERAPEUTICS

DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression

(2017) Alexis R. Barr et al.   Nature Communications

Prolonged mitotic arrest induced by Wee1 inhibition sensitizes breast cancer cells to paclitaxel

(2017) Cody W. Lewis et al.   Oncotarget

Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition

(2017) Xiaoguang Wang et al.   HAEMATOLOGICA

Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma

(2016) Elliot Kahen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) H. Tilly et al.   ANNALS OF ONCOLOGY

AID-associated DNA repair pathways regulate malignant transformation in a murine model of BCL6-driven diffuse large B-cell lymphoma

(2015) X. Gu et al.   BLOOD

The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs

(2015) R Visconti et al.   CELL DEATH AND DIFFERENTIATION

Chk1 and Wee1 control genotoxic-stress induced G2–M arrest in melanoma cells

(2015) Julio Vera et al.   CELLULAR SIGNALLING

Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study

(2015) Grzegorz S. Nowakowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

(2015) Khanh Do et al.   JOURNAL OF CLINICAL ONCOLOGY

Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma

(2015) Enrico Derenzini et al.   Oncotarget

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

(2014) Anas Younes et al.   LANCET ONCOLOGY

Identification of Early Replicating Fragile Sites that Contribute to Genome Instability

(2013) Jacqueline H. Barlow et al.   CELL

Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics In Vitro and In Vivo, Independent of p53 Functionality

(2013) A. A. Van Linden et al.   MOLECULAR CANCER THERAPEUTICS

Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption

(2012) H. Beck et al.   MOLECULAR AND CELLULAR BIOLOGY

WEE1 Kinase Inhibition Enhances the Radiation Response of Diffuse Intrinsic Pontine Gliomas

(2012) V. Caretti et al.   MOLECULAR CANCER THERAPEUTICS

WEE1 inhibition sensitizes osteosarcoma to radiotherapy

(2011) Jantine PosthumaDeBoer et al.   BMC CANCER

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

(2010) Hiroshi Hirai et al.   CANCER BIOLOGY & THERAPY

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Single-Stranded DNA Orchestrates an ATM-to-ATR Switch at DNA Breaks

(2009) Bunsyo Shiotani et al.   MOLECULAR CELL

Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: Contribution of DNA replication, transcription inhibition and Chk/p53 signaling

(2008) Michael Goldstein et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY